A phase 2, randomised, placebo-controlled study of guselkumab in adults with new-onset or relapsing giant cell arteritis
The study's primary endpoint (GC-free remission) was not met; results do not support the use of guselkumab in the treatment of GCA.
Authors
- Pauline Verdijk (ORCID: https://orcid.org/0000-0003-2272-2736)
- Linda Okonkwo
- Mark A. Ahlman (ORCID: https://orcid.org/0000-0003-3906-2084)
- Carolyn Ross (ORCID: https://orcid.org/0000-0002-2891-3245)
- M‐Y. HSU
- J. Henes
- Jean-Paul Makhzoum
- Daniel Blockmans
- Peter C. Grayson
- Maria C. Cid
- Maxime Samson
- Georgina Espigol-Frigole
- Shu Li
- Verena Schönau
Institutions
- Johnson & Johnson (United States) (US)
- Université de Bourgogne (FR)
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Augusta University (US)
- National Institute of Arthritis and Musculoskeletal and Skin Diseases (US)
- Universitätsklinikum Erlangen (DE)
- Hôpital du Sacré-Cœur de Montréal (CA)
- STZ eyetrial (DE)
- Johnson & Johnson (Netherlands) (NL)
- Consorci Institut D'Investigacions Biomediques August Pi I Sunyer (ES)
- Université Bourgogne Europe (FR)
- Universitat de Barcelona (ES)
- University of Tübingen (DE)
- KU Leuven (BE)
Publication Details
- Journal
- Annals of the Rheumatic Diseases
- Published
- 2026-02-01
- DOI
- https://doi.org/10.1016/j.ard.2026.01.009
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00